Obinutuzumab
Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA
SG Tylor
Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...
In patients with treatment-naive CLL, Venetoclax Plus Obinutuzumab Shows Durable Survival Benefits
SG Tylor
According to 6-year results from the Phase III CLL14 trial (NCT02242942), fixed-duration venetoclax (Venclexta) plus obinutuzumab (Gazyva) therapy resulted in ...
